Rheumatic Diseases
‚îú‚îÄ‚îÄ Autoimmune / Inflammatory (Connective Tissue Diseases)
‚îÇ   ‚îú‚îÄ‚îÄ Systemic lupus erythematosus (SLE)
‚îÇ   ‚îú‚îÄ‚îÄ Rheumatoid arthritis (RA)
‚îÇ   ‚îú‚îÄ‚îÄ Systemic sclerosis (SSc) / Scleroderma
‚îÇ   ‚îú‚îÄ‚îÄ Idiopathic inflammatory myopathies (IIM)
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ Polymyositis (PM)
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ Dermatomyositis (DM)
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ Inclusion body myositis (IBM)
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ Immune-mediated necrotizing myopathy (IMNM)
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ Overlap myositis (e.g., with SLE, SSc)
‚îÇ   ‚îú‚îÄ‚îÄ Sj√∂gren‚Äôs syndrome (SS)
‚îÇ   ‚îú‚îÄ‚îÄ Mixed connective tissue disease (MCTD)
‚îÇ   ‚îú‚îÄ‚îÄ Undifferentiated connective tissue disease (UCTD)
‚îÇ   ‚îú‚îÄ‚îÄ Psoriatic arthritis (PsA)
‚îÇ   ‚îú‚îÄ‚îÄ Reactive arthritis (ReA)
‚îÇ   ‚îú‚îÄ‚îÄ Ankylosing spondylitis (AS)
‚îÇ   ‚îî‚îÄ‚îÄ Other Spondyloarthropathies (SpA)
‚îÇ       ‚îú‚îÄ‚îÄ Enteropathic arthritis (IBD-associated)
‚îÇ       ‚îî‚îÄ‚îÄ Undifferentiated SpA
‚îÇ
‚îú‚îÄ‚îÄ Degenerative / Mechanical
‚îÇ   ‚îú‚îÄ‚îÄ Osteoarthritis (OA)
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ Primary (age-related)
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ Secondary (post-traumatic, metabolic, CPPD-related)
‚îÇ   ‚îú‚îÄ‚îÄ Degenerative disc disease
‚îÇ   ‚îú‚îÄ‚îÄ Meniscal and labral tears
‚îÇ   ‚îú‚îÄ‚îÄ Chondrocalcinosis-associated OA
‚îÇ   ‚îî‚îÄ‚îÄ Tendinopathies and bursitis (e.g., rotator cuff, trochanteric)
‚îÇ
‚îú‚îÄ‚îÄ Crystal-Induced Arthropathies
‚îÇ   ‚îú‚îÄ‚îÄ Gout (Monosodium urate, MSU)
‚îÇ   ‚îú‚îÄ‚îÄ Calcium pyrophosphate deposition disease (CPPD)
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ Often presents with **Chondrocalcinosis** on imaging
‚îÇ   ‚îî‚îÄ‚îÄ Basic calcium phosphate (BCP) deposition disease
‚îÇ       ‚îî‚îÄ‚îÄ Includes Milwaukee shoulder syndrome
‚îÇ
‚îú‚îÄ‚îÄ Vasculitis / Vascular Inflammatory Diseases
‚îÇ   ‚îú‚îÄ‚îÄ Large vessel vasculitis
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ Giant cell arteritis (GCA)
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ Takayasu arteritis
‚îÇ   ‚îú‚îÄ‚îÄ Medium vessel vasculitis
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ Polyarteritis nodosa (PAN)
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ Kawasaki disease
‚îÇ   ‚îî‚îÄ‚îÄ Small vessel vasculitis
‚îÇ       ‚îú‚îÄ‚îÄ ANCA-associated vasculitis (AAV)
‚îÇ       ‚îÇ   ‚îú‚îÄ‚îÄ Granulomatosis with polyangiitis (GPA, Wegener‚Äôs)
‚îÇ       ‚îÇ   ‚îú‚îÄ‚îÄ Microscopic polyangiitis (MPA)
‚îÇ       ‚îÇ   ‚îî‚îÄ‚îÄ Eosinophilic granulomatosis with polyangiitis (EGPA, Churg‚ÄìStrauss)
‚îÇ       ‚îî‚îÄ‚îÄ Immune complex vasculitis
‚îÇ           ‚îú‚îÄ‚îÄ IgA vasculitis (Henoch‚ÄìSch√∂nlein purpura)
‚îÇ           ‚îî‚îÄ‚îÄ Cryoglobulinemic vasculitis
‚îÇ
‚îú‚îÄ‚îÄ Metabolic / Systemic
‚îÇ   ‚îú‚îÄ‚îÄ Hemochromatosis arthropathy
‚îÇ   ‚îú‚îÄ‚îÄ Wilson‚Äôs disease (rare joint involvement)
‚îÇ   ‚îú‚îÄ‚îÄ Endocrine arthropathies
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ Hyperparathyroidism
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ Hypothyroidism
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ Acromegaly
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ Diabetes-related cheiroarthropathy
‚îÇ   ‚îî‚îÄ‚îÄ Amyloid arthropathy
‚îÇ
‚îî‚îÄ‚îÄ Other Connective Tissue / Rare or Overlapping Disorders
    ‚îú‚îÄ‚îÄ Fibromyalgia (central pain sensitization)
    ‚îú‚îÄ‚îÄ Relapsing polychondritis
    ‚îú‚îÄ‚îÄ Ehlers‚ÄìDanlos syndrome (EDS)
    ‚îú‚îÄ‚îÄ Marfan syndrome
    ‚îú‚îÄ‚îÄ Hypermobility spectrum disorder
    ‚îú‚îÄ‚îÄ Sarcoidosis (systemic granulomatous disease with arthritis)
    ‚îî‚îÄ‚îÄ IgG4-related disease (systemic fibroinflammatory disorder)



Excellent question üëç ‚Äî among **rheumatic diseases**, the *most researched* ones usually correlate with their **high prevalence (ÂèëÁóÖÁéá)** and **clinical importance (Â§öÂô®ÂÆòÊçüÂÆ≥„ÄÅËá¥ÊÆãÊÄß)**.

Let‚Äôs summarize by **both research attention and incidence**, grouped by category üëá

---

## ü©∫ **1. Autoimmune / Inflammatory Rheumatic Diseases (Á≥ªÁªüÊÄßËá™Ë∫´ÂÖçÁñ´ÊÄßÈ£éÊπøÁóÖ)**

| Disease                                    | Research intensity | Approx. Prevalence                         | Notes                                                                                                 |
| ------------------------------------------ | ------------------ | ------------------------------------------ | ----------------------------------------------------------------------------------------------------- |
| **Rheumatoid arthritis (RA)**              | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê (very high)  | ~0.5‚Äì1% of adults                          | Classic autoimmune arthritis; major model for immunopathogenesis and biologic drugs (anti-TNF, IL-6). |
| **Systemic lupus erythematosus (SLE)**     | ‚≠ê‚≠ê‚≠ê‚≠ê               | ~30‚Äì100 per 100,000                        | Strongly studied; complex genetics, affects young women, multi-organ involvement.                     |
| **Sj√∂gren‚Äôs syndrome (SS)**                | ‚≠ê‚≠ê‚≠ê                | ~0.1‚Äì0.5%                                  | Common after RA and SLE; dry eyes/mouth; overlaps with many CTDs.                                     |
| **Systemic sclerosis (SSc)**               | ‚≠ê‚≠ê                 | ~10‚Äì30 per 100,000                         | Rare but high mortality; heavily researched for fibrosis and vasculopathy.                            |
| **Polymyositis / Dermatomyositis (PM/DM)** | ‚≠ê‚≠ê                 | ~5‚Äì10 per 100,000                          | Lower incidence but significant because of cancer association and muscle immunopathology.             |
| **Mixed connective tissue disease (MCTD)** | ‚≠ê                  | Rare                                       | Overlap of SLE/SS/SSc/PM; moderate research.                                                          |
| **Ankylosing spondylitis (AS)**            | ‚≠ê‚≠ê‚≠ê‚≠ê               | ~0.1‚Äì0.5% (higher in HLA-B27+ populations) | Heavily studied; prototype for spondyloarthritis and IL-17 biology.                                   |
| **Psoriatic arthritis (PsA)**              | ‚≠ê‚≠ê‚≠ê‚≠ê               | ~0.1‚Äì0.3%                                  | Increasing research due to link with psoriasis and metabolic syndrome.                                |

---

## ‚öôÔ∏è **2. Degenerative / Mechanical**

| Disease                                       | Research intensity | Prevalence                             | Notes                                                                                     |
| --------------------------------------------- | ------------------ | -------------------------------------- | ----------------------------------------------------------------------------------------- |
| **Osteoarthritis (OA)**                       | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê (very high)  | >10% of adults (most common arthritis) | Extremely common; aging-related; hot research in cartilage regeneration and biomechanics. |
| **Degenerative disc disease**                 | ‚≠ê‚≠ê‚≠ê                | Very common (esp. elderly)             | Often studied under spine or orthopedic research.                                         |
| **Chondrocalcinosis-associated OA (CPPD-OA)** | ‚≠ê‚≠ê                 | ~5% elderly                            | Moderate research; overlaps with crystal arthropathy field.                               |

---

## üíé **3. Crystal-Induced Arthropathies**

| Disease                       | Research intensity | Prevalence                     | Notes                                                                                               |
| ----------------------------- | ------------------ | ------------------------------ | --------------------------------------------------------------------------------------------------- |
| **Gout (MSU)**                | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê              | ~1‚Äì4% adults (rising globally) | Very common; major metabolic‚Äìrheumatic overlap; well-studied in purine metabolism and inflammation. |
| **CPPD disease (Pseudogout)** | ‚≠ê‚≠ê                 | ~4‚Äì7% elderly                  | Less common than gout but increasingly studied; often linked to OA.                                 |

---

## ü©∏ **4. Vasculitis / Vascular Inflammatory**

| Disease                                         | Research intensity | Prevalence                 | Notes                                                           |
| ----------------------------------------------- | ------------------ | -------------------------- | --------------------------------------------------------------- |
| **ANCA-associated vasculitis (GPA, MPA, EGPA)** | ‚≠ê‚≠ê‚≠ê                | ~20 per 100,000            | Rare but intensively studied for autoantibody mechanisms.       |
| **Giant cell arteritis (GCA)**                  | ‚≠ê‚≠ê‚≠ê                | ~200 per million >50 years | Most common systemic vasculitis in elderly; closely researched. |
| **Takayasu arteritis**                          | ‚≠ê‚≠ê                 | ~2‚Äì3 per million           | Rare; studied mainly in Asia.                                   |

---

## ‚öñÔ∏è **5. Metabolic / Systemic**

| Disease                                             | Research intensity | Prevalence                    | Notes                                    |
| --------------------------------------------------- | ------------------ | ----------------------------- | ---------------------------------------- |
| **Hemochromatosis arthropathy**                     | ‚≠ê                  | <0.1%                         | Limited but mechanistically interesting. |
| **Endocrine arthropathies (e.g. diabetes-related)** | ‚≠ê                  | Common but less rheum-focused | Usually studied in endocrinology.        |

---

## üåø **6. Other / Overlap**

| Disease                    | Research intensity | Prevalence   | Notes                                                    |
| -------------------------- | ------------------ | ------------ | -------------------------------------------------------- |
| **Fibromyalgia**           | ‚≠ê‚≠ê‚≠ê‚≠ê               | ~2‚Äì4% adults | Very common, widely studied in pain neuroscience.        |
| **Ehlers‚ÄìDanlos & Marfan** | ‚≠ê‚≠ê                 | Rare         | Research focused on genetics, connective tissue biology. |
| **IgG4-related disease**   | ‚≠ê‚≠ê                 | Emerging     | Newly recognized systemic fibroinflammatory disorder.    |

---

## üîù **Summary ‚Äî Top 5 by both Research & Prevalence**

| Rank | Disease                                                         | Reasons for Research Prominence                                     |
| ---- | --------------------------------------------------------------- | ------------------------------------------------------------------- |
| ‚ë†    | **Rheumatoid arthritis (RA)**                                   | High prevalence, model autoimmune disease, many biologic therapies. |
| ‚ë°    | **Osteoarthritis (OA)**                                         | Extremely common, major cause of disability, aging-related.         |
| ‚ë¢    | **Systemic lupus erythematosus (SLE)**                          | Complex immunopathology, female predominance, multi-system.         |
| ‚ë£    | **Gout**                                                        | Common, metabolic‚Äìinflammatory link, diet/lifestyle relevance.      |
| ‚ë§    | **Ankylosing spondylitis (AS)** / **Psoriatic arthritis (PsA)** | Immunologic insight (IL-17/IL-23 axis), targeted biologics.         |

---

Would you like me to make a **chart (prevalence vs. research intensity)** so you can visually compare which diseases dominate rheumatology research worldwide?
